Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma	Neoplasms by Histologic Type, neoplasm, plasma cell neoplasm	Recruiting	Phase 2	2025-12-03		NCT06947083

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
H. Lee Moffitt Cancer Center and Research Institute	162
Pfizer	431

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Moffitt Cancer Center	Tampa	United States	523

Clinical trials